Cirrhosis Clinical Trial
Official title:
Tunnelated Peritoneal Catheter Versus Repeated Large Volume Paracentesis for Diuretic Resistant Ascites in Patients With Cirrhosis: An Investigator Initiated, Open, Parallel Arm Randomized Controlled Trial
Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small
volume fluid drainage at home. The treatment may improve the management of ascites and have a
beneficial effect on the quality of life.
This study aims to evaluate the beneficial and harmful effects of the peritoneal catheter
(PleurX) versus repeated large volume paracentesis for patients with cirrhosis and diuretic
resistant ascites.
The trial is an investigator initiated, randomised, single blind, parallel arm, controlled
trial.
Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will
receive ciprofloxacin to prevent spontaneous bacterial peritonitis.
We will include 32 adult patients with cirrhosis Duration of trial 18 months. The total
duration of follow up is six months. The primary outcome is paracentesis free survival.
Ten percent of patients with cirrhosis develop ascites. In 90% of patients, ascites can be
treated with diuretics. The management of the remaining 10% with diuretic resistant ascites
is challenging. Symptoms including abdominal pain, dyspnoea, nausea, vomiting, and anorexia
have a detrimental impact on the quality of life. Repeated large volume paracentesis provides
only temporary improvement of symptoms.
Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small
volume fluid drainage at home. The treatment may improve the management of ascites and have a
beneficial effect on the quality of life.
To evaluate the beneficial and harmful effects of the peritoneal catheter (PleurX) versus
repeated large volume paracentesis for patients with cirrhosis and diuretic resistant
ascites.
Investigator initiated, randomised, single blind, parallel arm, controlled trial.
Due to the nature of the intervention and the primary outcome measure, Investigators are
unable to conduct the trial with blinding of the patients, the investigators or use blinded
outcome assessment.
Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will
receive ciprofloxacin to prevent spontaneous bacterial peritonitis.
The study investigators will include 32 adult patients with cirrhosis of any aetiology and
diuretic resistant ascites.
Gastrounit, Hvidovre University Hospital, Department of Gastroenterology and Hepatology,
Odense University Hospital, Department of Gastroenterology and Hepatology, Aarhus University
Hospital, and Centre for Hepatology, UCL Institute for Liver and Digestive Health, Royal Free
Campus, University College London, UK 18 months. The total duration of follow up is six
months. The primary outcome is paracentesis free survival. Secondary outcomes include
cumulative number of paracentesis, cirrhosis-related complications, safety, quality of life,
changes in metabolic and nutritional parameters, circulatory dysfunction, renal function,
cardiac output, neuro-humoral changes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT05538546 -
Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A |